Posted by Danielle Matia on July 02, 2012
Physicians worldwide who are interested in learning more about the GeneXpert which can be used for monitoring CML patients may wish to sign up for Cepheid’s upcoming webinar July 5th entitled, "Analytical and economic evaluation of the fully automated Xpert BCR-ABL Monitor Assay".
Click here to register for their online program!
Analytical and economic evaluation of the fully automated Xpert BCR-ABL Monitor Assay
Thursday, July 5, 2012
4:00 PM - 5:00 PM BST (British Standard Time)
8:00 AM - 9:00 AM PST; 11:00 AM - 12:00 PM EST
Dr Jean-Michel Cayuela
Associate Professor, University Paris 7 Denis Diderot
Head, Department of Molecular Haematology, Saint-Louis Hospital
From webinar announcement:
Please join us to hear Dr. Jean-Michel Cayuela provide an introduction to molecular pathology, targeted therapy and the importance of treatment response monitoring within chronic myeloid leukaemia (CML). Dr. Cayuela will also discuss current BCR-ABL fusion transcript quantitation and standardization challenges. Additionally, he will introduce the latest Cepheid Xpert® BCR-ABL* assay, a valuable tool for monitoring patient treatment in a standardized way that allows for data alignment on the International Scale.
In collaboration with the French Group of Molecular Biologists for Malignant Haemopathies (GBMHM), Dr. Jean-Michel Cayuela pioneered a health economics approach to comparing homebrew and automated PCR assays for BCR-ABL monitoring. In this workshop Dr. Cayuela will share original data about the economic impact of an innovative program initiated in France for quality assurance of molecular monitoring of CML patients.
Dr. Jean-Michel Cayuela is Associate Professor at University Paris 7 Denis Diderot and Head of the Department of Molecular Haematology at Saint-Louis Hospital, Paris. He has researched and published on treatment response monitoring in haematological malignancies, including CML which was published in the journal Haematologica in 2010.